1.
Ponatinib versus imatinib for newly diagnosed chronic myeloid leukaemia: an international, randomised, open-label, phase 3 trial
by Lipton, Jeffrey H, Prof
The lancet oncology, 2016, Vol.17 (5), p.612-621
2.
Efficacy and safety of TMC125 (etravirine) in treatment-experienced HIV-1-infected patients in DUET-1: 24-week results from a randomised, double-blind, placebo-controlled trial
by Madruga, José Valdez, Dr
The Lancet (British edition), 2007, Vol.370 (9581), p.29-38
3.
Efficacy and safety of TMC125 (etravirine) in treatment-experienced HIV-1-infected patients in DUET-2: 24-week results from a randomised, double-blind, placebo-controlled trial
by Lazzarin, Adriano, Prof
The Lancet (British edition), 2007, Vol.370 (9581), p.39-48
4.
Cardiovascular Toxicity in Cancer Patients Treated with Tyrosine Kinase Inhibitors: A Real-World Single-Center Experience
by Novo, Giuseppina
Oncology, 2020, Vol.98 (7), p.445-451
5.
Efficacy and safety of intravenous levosimendan compared with dobutamine in severe low-output heart failure (the LIDO study): a randomised double-blind trial
by Follath, F
The Lancet (British edition), 2002, Vol.360 (9328), p.196-202
6.
A phase 1 study of the safety, tolerability, pharmacokinetics, and pharmacodynamics of TAK-063, a selective PDE10A inhibitor
by Tsai, Max
Psychopharmacology, 2016, Vol.233 (21-22), p.3787-3795
7.
Levosimendan in patients with left ventricular systolic dysfunction undergoing cardiac surgery on cardiopulmonary bypass: Rationale and study design of the Levosimendan in Patients...
by Mehta, Rajendra H
The American heart journal, 2016, Vol.182, p.62-71
8.
Phase 2 double-blind, randomized trial of etravirine versus efavirenz in treatment-naive patients: 48-week results
by GAZZARD, Brian
AIDS (London), 2011, Vol.25 (18), p.2249-2258
9.
10.
Safety and Feasibility of Levosimendan Administration in Takotsubo Cardiomyopathy: A Case Series
by Santoro, Francesco
Cardiovascular therapeutics, 2013, Vol.31 (6), p.e133-e137
11.
Unique Cutaneous Reaction to Second- and Third-Generation Tyrosine Kinase Inhibitors for Chronic Myeloid Leukemia
by Patel, Anisha B
Dermatology (Basel), 2016, Vol.232 (1), p.122-125
12.
The role of ponatinib in Philadelphia chromosome-positive acute lymphoblastic leukemia
by Sanford, David S
Expert review of anticancer therapy, 2015, Vol.15 (4), p.365-373
13.
Safety, pharmacokinetic, and positron emission tomography evaluation of serotonin and dopamine transporter occupancy following multiple-dose administration of the triple monoamine...
by Zheng, Ming
Psychopharmacology, 2014, Vol.232 (3), p.529-540
14.
Evaluation of safety and tolerability, pharmacokinetics, and pharmacodynamics of BMS-820836 in healthy subjects: a placebo-controlled, ascending single-dose study
by Risinger, Robert
Psychopharmacology, 2013, Vol.231 (11), p.2299-2310
15.
A randomized crossover study to compare efavirenz and etravirine treatment
by NGUYEN, Alain
AIDS (London), 2011, Vol.25 (1), p.57-63
16.
ARIES-3: Ambrisentan Therapy in a Diverse Population of Patients with Pulmonary Hypertension
by Badesch, David B.
Cardiovascular therapeutics, 2012, Vol.30 (2), p.93-99
17.
Frequency of Edema in Patients With Pulmonary Arterial Hypertension Receiving Ambrisentan
by Shapiro, Shelley, MD, PhD
The American journal of cardiology, 2012, Vol.110 (9), p.1373-1377
18.
Etravirine-based antiretroviral therapy in HIV/hepatitis C virus coinfected advanced fibrosis patients receiving triple therapy against hepatitis C virus with telaprevir
by Ramirez, Maria Luisa Montes
AIDS (London), 2014, Vol.28 (16), p.2487-2489
19.
An open-label assessment of TMC 125: a new, next-generation NNRTI, for 7 days in HIV-1 infected individuals with NNRTI resistance
by GAZZARD, Brian G
AIDS (London), 2003, Vol.17 (18), p.F49-F54
20.
A comparison of neuropsychiatric adverse events during 12 weeks of treatment with etravirine and efavirenz in a treatment-naive, HIV-1-infected population
by NELSON, Mark
AIDS (London), 2011, Vol.25 (3), p.335-340
